SCHEMBL6945952

SCHEMBL6945952

COCc1c(O)nc(Cc2ccc3c(c2)OCO3)nc1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CALM1 P0DP23 3/20 0.47
CYP3A4 P08684 1/20 0.47
HSD17B10 Q99714 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
ALDH1A1 P00352 1/20 0.43
NPC1 O15118 1/20 0.43
LMNA P02545 1/20 0.43
HPGD P15428 1/20 0.43
RAB9A P51151 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
HSP90AB1 P08238 1/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
ATM Q13315 1/20 0.43
LTB4R Q15722 1/20 0.43
IGFBP3 P17936 1/20 0.41
CYP2D6 P10635 1/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A4 P31645 1/20 0.41
SLC6A3 Q01959 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6945057 0.85 ALDH1A1 (0.46) CALM1CYP3A4HSD17B10ALDH1A1HSP90AB1
SCHEMBL6942002 0.85 CALM1 (0.45) CALM1CYP3A4HSD17B10SMN1; SMN2ALDH1A1
SCHEMBL6947220 0.85 SMN1; SMN2 (0.44) CALM1CYP3A4HSD17B10SMN1; SMN2ALDH1A1
SCHEMBL6942703 0.84 CALM1 (0.49) CALM1CYP3A4HSD17B10SMN1; SMN2ALDH1A1
SCHEMBL6943282 0.83 SMN1; SMN2 (0.49) CYP3A4HSD17B10SMN1; SMN2ALDH1A1NPC1
SCHEMBL6942293 0.82 ALDH1A1 (0.51) CALM1CYP3A4HSD17B10ALDH1A1L3MBTL1
SCHEMBL6937614 0.80 SMN1; SMN2 (0.51) CYP3A4HSD17B10SMN1; SMN2ALDH1A1NPC1
SCHEMBL6942147 0.78 CALM1 (0.49) CALM1CYP3A4HSD17B10ALDH1A1GAA
SCHEMBL6939898 0.78 GAA (0.49) CALM1CYP3A4ALDH1A1HPGDGAA
SCHEMBL6944322 0.77 MAOB (0.53) CALM1SMN1; SMN2ALDH1A1NPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1268471-B1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS SCHERING AG (DE) 2003-10-15 EP disclosed
US-6525051-B2 N-heterocyclic derivatives as NOS inhibitors SCHERING AKTIENGESELLSCHAFT (DE) 2003-02-25 US disclosed
EP-1268471-A1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS SCHERING AKTIENGESELLSCHAFT (DE) 2003-01-02 EP disclosed
US-20020010190-A1 N-heterocyclic derivatives as NOS inhibitors SCHERING AKTIENGESELLSCHAFT (DE) 2002-01-24 US disclosed
WO-2001072744-A1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS SCHERING AKTIENGESELLSCHAFT (DE) 2001-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010190-A1 N-heterocyclic derivatives as NOS inhibitors NOS1, NOS3, NOS2 CALM1 1648/4885CYP3A4 46/4885HSD17B10 692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.